Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,240.0
5.5 (0.17%)

 

  • STI Straits Times Index
    3,240.0
    5.5 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    31.3 (0.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,827.2
    31.7 (0.13%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,244.1
    -5.1 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,203.2
    4.2 (0.06%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 872.5M
  • Value: 729.0M
  • Rise: 113
  • Fall: 130
  • Unch: 575

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.104-0.001
ThaiBev0.795+0.005
Rex Intl0.181+0.007
Spackman0.018+0.002
Golden Agri-Res0.225-
Genting Sing0.910-0.005
Joyas Intl0.003-
OEL0.023-0.001
YZJ Shipbldg SGD1.040-0.020
AusGroup^0.042+0.003

World Indices

World Indices
Name Last Change
Nasdaq 9,314.9 -87.6
HSI 27,940.5 +31.3
HSCEI 10,969.3 +17.0
Jakarta 6,244.1 -5.1
Nikkei 225 23,827.2 +31.7
SSE Comp 2,976.5
Shanghai A 3,118.9
Shanghai B 248.6
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CATALYST BIOSCIENCES INC CATALYST BIOSCIENCES
Updated on 24 Jan 2020 (End of trading day)
Last (USD): 6.720 Change: -0.130 High: 6.900 Remarks: -
Change (%): -1.90 Low: 6.520
Open 6.900 Yesterday's Close 6.85
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 89,671 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -2.49606 Trailing EPS (USD) e -4.35230 NAV (USD) b 6.7496
PE a - Trailing PE f - Price / NAV b 0.9956
Dividend (USD) d - Cash In Hand (USD) g 1.9116 Issued & Paid-up Shares c 12,041,000
Dividend Yield (%) d - Price / Cash In Hand g 3.515 Treasury Shares h -
Beta - 75 Daysi 2.051 R-Squared - 75 Days(%)i 1.21 Market Cap (M) 80.916
Beta - 500 Daysi -0.065 R-Squared - 500 Days (%)i 0.02 Enterprise Value (M) -2.119
Piotroski F Score 2 Exchange Code CBIO Par Value ( $ ) n.a.
52 Weeks Volatility (%) 73.81 Free Float (%) 90.8
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 11 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 20 Aug 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CATALYST BIOSCIENCES INC NASDAQ 80.916 - - 0.9956 -
Industry Biotechnology NASDAQ 2,333.943 369.657 92.382 5.8148 0.757
Local Peer AMGEN INC NASDAQ 134,041.969 15.969 16.616 12.2671 2.480
Local Peer GILEAD SCIENCES INC NASDAQ 79,894.223 14.646 29.667 3.8776 3.659
Local Peer VERTEX PHARMACEUTICAL NASDAQ 58,902.779 28.097 27.476 11.2123 -
Local Peer BIOGEN INC NASDAQ 50,188.138 11.327 9.302 3.5859 -
Local Peer ILLUMINA INC NASDAQ 46,978.260 56.874 48.282 10.5831 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,910.353 15.509 17.680 3.6090 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,295.304 300.197 15.844 2.2470 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,464.308 - - 10.9374 -
Local Peer INCYTE CORPORATION NASDAQ 16,529.566 150.965 40.817 6.8233 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,474.694 - - 5.0334 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,961.357 - 48.206 5.4130 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,378.800 - - 8.3249 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), XENCOR INC (NASDAQ), VIELA BIO INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), ALECTOR INC (NASDAQ), REGENXBIO INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), IMMUNOGEN INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AVROBIO INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MACROGENICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), TRANSLATE BIO INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), COMPUGEN (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), IVERIC BIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), KAMADA (NASDAQ), GERON CORP (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AFFIMED N V (NASDAQ), SERES THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), XOMA CORP (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), CONTRAFECT CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VACCINEX INC (NASDAQ), COHBAR INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), TREVENA INC (NASDAQ), ORGENESIS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), ZAFGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), VAXART INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), TROVAGENE INC (NASDAQ), BIOCEPT INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SENESTECH INC (NASDAQ), OPGEN INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 141,021.137 52.562 52.563 18.8452 0.854
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,376.752 86.636 25.562 5.7660 0.692
Global Peer SINO BIOPHARM HKEx 143,847.408 13.425 13.933 4.2839 0.640
Global Peer WUXI BIO HKEx 134,349.414 179.875 140.620 13.8295 -
Global Peer BEIGENE HKEx 100,670.850 - - 10.0445 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 33,091.696 199.005 - 9.3319 -
Global Peer 3SBIO HKEx 27,939.670 18.469 22.480 2.7538 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,891.976 46.124 672.553 2.7942 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), KADMON HLDGS INC (NYSE), ASCENTAGE-B (HKEx), NANOVIRICIDES INC (NYSE American), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), TELIX PHARMACEUTIC (ASX), PFENEX INC (NYSE American), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CEL-SCI CORP (NYSE American), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOTRON (ASX), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), ANTEOTECH LIMITED (ASX), REGENT PACIFIC (HKEx), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), IBIO INC (NYSE American), ORAGENICS INC (NYSE American), CCP TECHNOLOGIES LTD (ASX), EXTRAWELL PHAR (HKEx), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), QT Vascular (SGX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.660
-8.94 %
10 Days ---
20 Days --0.040
-0.59 %
Medium Term Return 3 Months -+1.100
+19.57 %
6 Months --1.320
-16.42 %
1 Year --0.950
-12.39 %
Long Term Return 2 Years --18.050
-72.87 %
3 Years --2.430
-26.56 %
Annualised Return Annualised --
-9.78 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 4.520 - 10.840 Change From 1 Year Low +2.200 % Change From 1 Year Low (%) +48.67
Change From 1 Year High -4.120 % Change From 1 Year High (%) -38.01
2 Years Range 4.520 - 37.000 Change From 2 Years Low +2.200 % Change From 2 Years Low (%) +48.67
Change From 2 Years High -30.280 % Change From 2 Years High (%) -81.84
5 Years Range 3.110 - 324.000 Change From 5 Years Low +3.610 % Change From 5 Years Low (%) +116.08
Change From 5 Years High -317.280 % Change From 5 Years High (%) -97.93
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
24 Jan 2020 6.900 6.900 6.520 6.720 89,671 -
23 Jan 2020 7.130 7.130 6.750 6.850 138,738 -
22 Jan 2020 7.100 7.190 7.020 7.190 78,024 -
21 Jan 2020 7.350 7.450 7.020 7.130 89,374 -
17 Jan 2020 7.320 7.480 7.230 7.380 153,775 -
16 Jan 2020 7.300 7.411 7.240 7.320 180,946 -
15 Jan 2020 6.850 7.470 6.850 7.290 221,514 -
14 Jan 2020 6.780 7.160 6.770 6.890 117,140 -
13 Jan 2020 6.680 6.920 6.620 6.790 114,280 -
10 Jan 2020 6.660 6.820 6.620 6.720 75,820 -
09 Jan 2020 6.510 6.930 6.510 6.650 134,296 -
08 Jan 2020 6.510 6.600 6.380 6.560 114,561 -
07 Jan 2020 6.450 6.620 6.350 6.540 78,222 -
06 Jan 2020 6.490 6.516 6.330 6.450 100,867 -
03 Jan 2020 6.450 6.590 6.330 6.530 128,545 -
02 Jan 2020 6.810 6.930 6.380 6.500 224,166 -
31 Dec 2019 6.520 6.910 6.510 6.810 146,311 -
30 Dec 2019 6.760 6.990 6.500 6.520 246,922 -
27 Dec 2019 7.360 7.370 6.730 6.760 410,539 -
26 Dec 2019 7.240 7.680 7.200 7.330 421,576 -
24 Dec 2019 7.330 7.440 7.160 7.310 226,249 -
23 Dec 2019 7.510 7.770 7.210 7.400 718,223 -
Summary
Current 2 Weeks
(10 Jan 2020 to 24 Jan 2020)
6.660 7.480 6.520 6.720 1,259,282 -
Previous 2 Weeks
(26 Dec 2019 to 09 Jan 2020)
7.240 7.680 6.520 6.650 2,006,005 -
4 Weeks from
(26 Nov 2019 to 24 Dec 2019)
5.410 7.480 5.180 7.310 26,129,784 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.